the original fmcg company deal

When is news regarding our FMCG Company due?

Well, here's a bit of catch-up reading before my reasonably well researched answer is offered at the conclusion.

Wednesday, 22 February 2006
OBJ Appoints Director of Business Development
========================================================
OBJ is pleased to announce the appointment of Mr. Glyn Denison to the Board of Directors.
Mr Denison will oversee the commercial and market development activities of the company. Mr Denison has 30 years experience in international business development including 16 years in technology intensive industries, during which time he oversaw annual company revenues rise from a small base to over $450m per annum.

Mr Denison has worked in Europe, China, South East Asia and Australia and has extensive networks and contacts across the European medical sector.

Wednesday, 19 April 2006
OBJ's DRUG DELIVERY TECHNOLOGY PROVEN IN HUMAN TRIAL
==============================================
OBJ Limited announced today that Curtin University, in Western Australia, had successfully completed a blinded placebo controlled human pilot study into the effects of the company's drug delivery technology on the speed of onset of a commercially available Tetracaine local anesthetic. The study was designed to investigate the skin penetration enhancement of Dermaportation in vivo using loss of sensation due to local anaesthetic gel as a pharmacodynamic measure of skin penetration of the local anaesthetic drug amethocaine/ tetracaine.

Thursday 23rd November 2006
OBJ ANNOUNCES POWER-LESS ACTIVE DRUG PATCH
========================================
OBJ is pleased to announce the development of what is believed to be the first power-less active drug patch technology. The program was established to determine how OBJ's expertise in non-contact active drug delivery techniques could be applied to create a new type of drug patch substrate with the ability to drive larger and more complex molecules through the skin.
Traditional drug patches, such as those used in smoking cessation and hormone replacement, use a drug and adhesive matrix that relies on the slow migration of drug molecules from the matrix into the skin. This has restricted the commercial use of drug patches to simple molecules and low dose applications. A change in the underlying capabilities of drug patch technology would be expected to impact significantly on this market.

Tuesday, 9 January 2007
FORMER ALZA EXECUTIVE DIRECTOR TO ADVISE OBJ'S BUSINESS AND LICENSING DEVELOPMENTS IN NORTH AMERICA
=====================================================
OBJ is pleased to announce that Dr Ravi Kiron PhD, MBA, one of the authorities on drug delivery licensing and technology evaluation and former- Executive Director of ALZA Corporation, a division of the $200 billion US pharmaceutical company Johnson & Johnson, will advise OBJ on a consultancy basis to assist the growth of its transdermal drug delivery products and licensing business.

Investor Update Ann June 2007
*Initiated BD discussions with majority of large pharma
*Signed Feasibility Agreement with large pharma for undisclosed application
*Signed Feasibility Agreement with GSK for multiple applications in Consumer Healthcare
*Initiated BD discussions with potential cosmetic partners

In December 2007 OBJ executed a research collaboration agreement with a Global FMCG company to conduct an initial feasibility to evaluate the use of both the DP and ETP platforms for up to 2 compounds for OTC healthcare applications.

The initial feasibility was successfully completed in March 2008. The FMCG Company then advised OBJ that it wished to conduct additional studies to further evaluate the magnetic delivery platforms for 1 of the previously tested OTC compounds.
The terms of the agreement and details of the feasibility project still remain subject to confidentiality; however OBJ did receive fees of up to US$335,000 on completion of that project. The agreement also dealt with future collaboration and potential licensing rights that may arise following that successful feasibility.

October 29, 2008
OBJ SIGNS SECOND AGREEMENT WITH GLOBAL FMCG COMPANY
OBJ announced that they had executed a second research collaboration agreement with a global FMCG Company to evaluate and optimize its proprietary DP and ETP drug delivery platforms for the transdermal delivery of an undisclosed compound. The feasibility project compared the in vitro skin penetration amount and rate of mthe target drug delivered by DP, ETP and a commercial formulation.

US STUDY RESULTS October 1, 2009

OBJ advised that they received the final report from Azopharma covering the Company's research collaboration with the global Fast Moving Consumer Goods company. The report by Azopharma set out the results of an eight-month patch development and evaluation program. The study tested the delivery performance of OBJ's Dermaportation and ETP technologies in a fully formulated patch format, when compared to their existing Over the Counter drug product with significant international sales.
The FMCG companys stated objective in the Agreement with OBJ was to achieve up to a 10- fold increase in drug delivery over an existing commercial product. Under the terms of the Agreement, OBJ was restricted from disclosing any information relating to the drug tested, the comparative product or the market. The Azopharma Report which remains the property of the FMCG company did however state:
The developed patch system effectively fluxes approximately a 10-fold over the existing product comparatively
The development work to this point justifies proof-of concept of the formulation and technology to proceed further into the pharmaceutical development of a drug product.
Spare a moment to think about what the above has stated here: Both of our technologies in a patch format is already proven 10x more effective than the FMCG companys existing product already on the retail shelves with significant international sales and revenue
These test results are significant to the Company to the extent that attention to development of selected patch products with suitable international partners can now become more focused. It is the intention of OBJ to expedite securing commercial partners to embrace the use of OBJ's patch technologies into the most appropriate applications.
___________________________________________________________
-----------------------------------------------------------

Now, I know I'm jumping 15 months forward from here but this is where imo the encrypted Anns start to unravel.

February 08, 2010
STATEMENT OF INTENT FROM MAJOR INTERNATIONAL FMCG COMPANY
OBJ is pleased to advise that it has received a Statement of Intent from a global FMCG company in regards to an ongoing product development program utilising OBJ's ETP and DP technologies.

This global FMCG company has permitted the release of the following statement:

OBJ is continuing to work with a MAJOR HEALTHCARE company to develop a product to enhance the delivery of one of their key therapeutic agents
The Company is pleased with the rapid progression of this program and will continue to keep shareholders updated.

Giving consideration that this release was permitted from the global FMCG company, one could ask, should the unencrypted version simply read like this:
OBJ is continuing to work with 3M in the development of a product to enhance the delivery of one of the global FMCG companys key therapeutic agents?
In 2007 OBJ executed a Collaboration Agreement with the major international FMCG company to explore the use of ETP and DP with two compounds for OTC use. This initial program was completed in March 2008 and in December 2008 the Company announced a second and larger technology optimization program, to be conducted in the USA at a facility operated by Azopharma Contract Services Inc. OBJ received approximately US$335,000 for the program. The outcomes of that program were summarized in the release to shareholders in October 2009 and indicated that the Company's technology had achieved the FMCG companys stated objectives.
Since October 2009 OBJ has continued to work with the FMCG company in the development of a product to enhance the delivery of one of their key therapeutic agents, and the Statement of Intent represents a continuation of that relationship.
And our 3M Ann
The Company announced a MTA with 3M in November 2009 and a subsequent extension to the program in January 2010 to accommodate the broadening of the testing program. Following the completion of that initial phase, OBJ and 3M have agreed to extend the testing and to work closely with OBJ's partners. 3M has granted permission to the release of the following commentary.

"This program of work is now complete and the other party to agreement has reconfirmed its interest in OBJ continuing to recommend that party as a potential contract manufacturer for magnetic arrays to interested partners"

"Additionally, OBJ has agreed to share the results of a product performance enhancement program for two existing commercial patch products."

More importantly what we should also keep in mind is that SINCE THAT TIME - February 2010 further updates regarding the development progress with our original major international FMCG company collaboration have been intentionally omitted from all reporting. Questioning Glyn in person on this matter he has simply only advised that they are "still progressing" which certainly only suggests to me that his lips remain firmly sealed until the next specific announcement.

So, after all that - when's our BIG DEAL DUE DATE?

As far as estimating when this big Ann is due, from all my experience there remains only one sure way of getting it spot on within a couple of days, which I'm sure Smilez and Steini, among others will also agree with me...

Sell all your shares!

And I'll be first to apologize I'm not willing to take this one for the team ;)

For those of you not expecting any positive news before the New Year I can offer one piece of advice where OBJ is always concerned...

Expect the unexpected!